| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.31175 |
| P698 | PubMed publication ID | 29171009 |
| P50 | author | Zhonghan Zhang | Q89390017 |
| Li Zhang | Q89390020 | ||
| P2093 | author name string | Yaxiong Zhang | |
| Fangfang Gao | |||
| Shen Zhao | |||
| P2860 | cites work | Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters | Q24617999 |
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | Q30356434 | ||
| Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents | Q30438696 | ||
| Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. | Q33345025 | ||
| Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer | Q33384455 | ||
| A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer | Q33397670 | ||
| Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer | Q33416842 | ||
| PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s | Q33418542 | ||
| Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. | Q33540289 | ||
| Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial | Q33600403 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Network meta-analysis using R: a review of currently available automated packages | Q34775962 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Graphical tools for network meta-analysis in STATA. | Q35009612 | ||
| Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies | Q35612977 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Use of indirect and mixed treatment comparisons for technology assessment | Q37259556 | ||
| Checking consistency in mixed treatment comparison meta-analysis | Q37705195 | ||
| Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis | Q37850174 | ||
| Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer | Q38062459 | ||
| Assessing key assumptions of network meta-analysis: a review of methods | Q38520487 | ||
| Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies | Q38523764 | ||
| Combined treatment strategies for microtubule stabilizing agent-resistant tumors | Q38908225 | ||
| Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses | Q39735046 | ||
| Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology | Q40244899 | ||
| Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | Q42073978 | ||
| Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer | Q42632045 | ||
| A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer | Q43260541 | ||
| Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. | Q44633976 | ||
| Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Tr | Q48053447 | ||
| BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. | Q51628000 | ||
| Markov chain Monte Carlo methods in biostatistics. | Q52289468 | ||
| Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. | Q53220080 | ||
| Inference from Iterative Simulation Using Multiple Sequences | Q56172083 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 1676-1688 | |
| P577 | publication date | 2017-12-04 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis | |
| P478 | volume | 142 |
| Q89497162 | Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 | cites work | P2860 |
Search more.